English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The rhodium (II) complexes Rh(2)(tfa)(4).2(tfac) and Rh(2)(tfacam)(4) (tfacam = CF(3)CONH-,tfa = CF(3)COO-,tfac = CF(3)CONH(2)) were synthesized and characterized by microanalysis and electronic and vibrational spectroscopies. Rh(2)(tfacam)(4) was tested both in vitro (U937 and K562 human leukemia cells and Ehrlich ascitic tumor cells) and in vivo for cytostatic activity and lethal dose determination, respectively. This is the first rhodium tetra-amidate to have its biological activity evaluated. The LD(50) value for Rh(2)(tfacam)(4) is of the same order as that of cisplatin, and it was verified that the rhodium complex usually needs lower doses than cisplatin to promote the same inhibitory effects.

metal-based drugs

<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mtext>Rh</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mtext>CF</mml:mtext></mml:mrow><mml:mn>3</mml:mn></mml:msub><mml:mtext>CONH</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>4</mml:mn></mml:msub></mml:math>: The First Biological Assays of a Rhodium (II) Amidate

Rh2(CF3CONH)4: The First Biological Assays of a Rhodium (II) Amidate